Alterity Therapeutics Ltd

ATH

Company Profile

  • Business description

    Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment: research and development into Parkinsonian and other neurodegenerative disorders.

  • Contact

    500 Collins Street
    Level 15
    MelbourneVIC3000
    AUS

    T: +61 393494906

    E: [email protected]

    https://www.alteritytherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2027

    Employees

    11

Stocks News & Analysis

stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.
stocks

Chart of the Week: Anthropic’s IPO range sits below our fair value

Our fair value is above the IPO range, but outcomes could differ widely.
stocks

Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released

Several gaming shares are trading at a discount to our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,850.0082.40-0.92%
CAC 408,146.8369.95-0.85%
DAX 4025,736.24309.13-1.19%
Dow JONES (US)50,198.17561.25-1.11%
FTSE 10010,551.17138.70-1.30%
HKSE23,294.75213.42-0.91%
NASDAQ24,429.88101.500.42%
Nikkei 22559,522.52498.240.84%
NZX 50 Index14,237.3526.94-0.19%
S&P 5007,323.6316.90-0.23%
S&P/ASX 2008,740.3081.50-0.92%
SSE Composite Index3,587.800.03-0.00%

Market Movers